Pulmonary fibrosis in COVID-19: mechanisms, consequences and targets
- PMID: 37191984
- DOI: 10.1093/qjmed/hcad092
Pulmonary fibrosis in COVID-19: mechanisms, consequences and targets
Abstract
Pulmonary fibrosis is characterized by extracellular deposition in the lung primarily collagen but also other ECM molecules. The primary cell type responsible for this is the myofibroblast, and this can be induced by various stressors and signals. Infections be they bacterial or viral can cause pulmonary fibrosis (PF). In 2019, severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) originated in Wuhan, China, has led to a worldwide pandemic and can lead to acute respiratory distress and lung fibrosis. The virus itself can be cleared, but patients may develop long-term PF, which can be debilitating and life-limiting. There is a significantly perturbed immune response that shapes the fibrotic response leading to fibrosis. Given the importance of PF irrespective of cause, understanding the similarities and differences in pathogenesis caused by SARS-CoV-2-induced PF may yield new therapeutic targets. This review examines the pathology associated with the disease and discusses possible targets.
© The Author(s) 2023. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Similar articles
-
Pulmonary fibrosis from molecular mechanisms to therapeutic interventions: lessons from post-COVID-19 patients.Biochem Pharmacol. 2021 Nov;193:114812. doi: 10.1016/j.bcp.2021.114812. Epub 2021 Oct 21. Biochem Pharmacol. 2021. PMID: 34687672 Free PMC article. Review.
-
Integrated Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unravels the Influences of SARS-CoV-2 Infections to Cancer Patients.Int J Mol Sci. 2022 Dec 10;23(24):15698. doi: 10.3390/ijms232415698. Int J Mol Sci. 2022. PMID: 36555339 Free PMC article.
-
Healing after COVID-19: are survivors at risk for pulmonary fibrosis?Am J Physiol Lung Cell Mol Physiol. 2021 Feb 1;320(2):L257-L265. doi: 10.1152/ajplung.00238.2020. Epub 2020 Dec 23. Am J Physiol Lung Cell Mol Physiol. 2021. PMID: 33355522 Free PMC article. Review.
-
From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic?Transl Res. 2022 Mar;241:13-24. doi: 10.1016/j.trsl.2021.09.001. Epub 2021 Sep 20. Transl Res. 2022. PMID: 34547499 Free PMC article. Review.
-
[Pulmonary fibrosis in patients with COVID-19: A review].Ter Arkh. 2022 Dec 26;94(11):1333-1339. doi: 10.26442/00403660.2022.11.201943. Ter Arkh. 2022. PMID: 37167174 Review. Russian.
Cited by
-
Influenza, SARS-CoV-2, and Their Impact on Chronic Lung Diseases and Fibrosis: Exploring Therapeutic Options.Am J Pathol. 2024 Oct;194(10):1807-1822. doi: 10.1016/j.ajpath.2024.06.004. Epub 2024 Jul 18. Am J Pathol. 2024. PMID: 39032604 Review.
-
Emerging roles of ferroptosis in pulmonary fibrosis: current perspectives, opportunities and challenges.Cell Death Discov. 2024 Jun 24;10(1):301. doi: 10.1038/s41420-024-02078-0. Cell Death Discov. 2024. PMID: 38914560 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous